BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amilpar: Relevant Fact - 3rd Issuance of Common Debentures


9/27/2010 8:53:54 AM

RIO DE JANEIRO, Sept. 24 /PRNewswire/ -- Amil Participacoes S.A. ("Amilpar"), in accordance with CVM Instruction 358, of January 3, 2002, informs that its Board of Directors approved today the 3rd Issuance of Common Debentures, not convertible into shares, with Floating Guarantee, up to four series, for public distribution, with restricted selling efforts ("Debentures") from Amilpar ("Restricted Offering" and "Issuance", respectively), according to CVM Instruction 476/09. Up to 900,000 (nine hundred thousand) Debentures will be issued, with a unit nominal value of R$ 1,000.00 (one thousand reais). The total amount of the issuance will be up to R$ 900,000,000.00 (nine hundred million reais).

The issuance will be made through up to 4 (four) series, in accordance with paragraph 3, article 59 of Brazilian Corporate Law. The Debentures of each series will have the following expiration dates: (a) 1st series: 3 (three) years from its issuance date, expiring on October 15, 2013; (b) 2nd series: 4 (four) years from its issuance date, expiring on October 15, 2014; (c) 3rd series: 5 (five) years from its issuance date, expiring on October 15, 2015; (d) 4th series: 5 (five) years from its issuance date, expiring on October 15, 2015.

The remuneration of the Debentures of 1st, 2nd, and 3rd series will be calculated exponentially and cumulatively, pro rata temporis, by elapsed work days, incident on the unit nominal value or the balance of the nominal value, since the issuance date or the date of payment of the respectively prior remuneration, as appropriate, until the respective expiration date, and paid at the end of each capitalization period.

The Offering aims exclusively qualified investors, according to items I and II, article 4, of CVM Instruction 476 and the public distribution registration in CVM is automatically exempt, pursuant to CVM Instruction 476.

Fitch attributed the rating AA- (bra) to the Offering, aligned with Amilpar's corporate rating.

To access the .pdf full version of the document visit our website at www.amilpar.com.br/ir

IR Contact

Erwin Kleuser

Investor Relations Officer

Phone: +55 (21) 3805-1155

invest@amil.com.br

www.amilpar.com.br/ir



About Amilpar

Amil Participacoes S.A. is the largest healthcare company in Brazil, according to the ANS, currently assisting over 5 million members in the states of Sao Paulo, Rio de Janeiro, Paran√°, Minas Gerais, Pernambuco, Bahia and in Distrito Federal.

SOURCE Amilpar



Read at BioSpace.com

Amilpar
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES